JP2017195830A - Food composition for adiposity prevention - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a food composition capable of improving metabolic syndrome, while aiming at new other applications, by utilizing a fact that a peptide extracted from an ovarian crust of salmon shows excellent effect in adiposity prevention.SOLUTION: There is provided a food composition for adiposity prevention mainly composed of a peptide extracted from an ovarian crust of salmon. The food composition is utilized, in addition to adiposity prevention, for some of liver function decrease suppression, blood glucose level control, blood pressure control, whitening effect improvement or climacteric disturbance improvement.SELECTED DRAWING: Figure 1

Description

  The present invention relates to a food composition mainly used for the prevention of fat accumulation characterized by comprising a peptide extracted from the ovary rind of salmon as a main component.

Traditionally, in fishery processing, streaks (ovary husks) left when processing salmon braids into salmon roe have been discarded without any particular use.
By the way, it is thought that the role of the ovary hull is to nourish and protect the fetus (fish egg), similar to the placenta of mammals. Therefore, the ovarian hull is an organ that can be called a fish placenta (placenta), and its effective utilization has been desired.

In response to such a request, a method for decomposing a contractile protein (myosin) that constitutes a fish egg shell has been proposed (see, for example, Patent Document 1).
In addition, as a use of the decomposed composition, it has been found that it has an action of suppressing a decrease in liver function, and based on this use, it has already been proposed to utilize the composition for the preparation of health foods and medicines. (For example, refer to Patent Document 2).

Japanese Patent No. 3691497 Japanese Patent No. 4247444

  However, peptides extracted from the ovarian rind of rabbits have not only been effective in suppressing liver function decline, but also have other new uses, such as being particularly effective in improving metabolic syndrome. Has been issued.

  The present invention has been made on the basis of such recent research results, and the peptide extracted from the ovary husk of moth exhibits excellent effects in preventing fat accumulation, thereby improving metabolic syndrome, It aims at providing the food composition which paid its attention also to the new use.

The gist of the present invention for achieving the object described above resides in the inventions of the following items.
[1] A food composition for preventing fat accumulation, comprising as a main component a peptide extracted from the ovary rind of salmon.
According to this food composition, the expression of a protein (UCP-1) that burns neutral fat of white adipocytes is increased. That is, adrenaline acts, and mitochondria burn white fat cells (visceral fat cells) and convert them into brown fat cells. Thereby, the metabolic syndrome is improved.

[2] A food composition for suppressing a decrease in liver function and preventing fat accumulation, comprising a peptide extracted from the ovary rind of salmon as a main component.
The food composition further has an antioxidant function (antitoxic effect) and suppresses liver function deterioration. Changes the proportion of good cholesterol (HDL) and bad cholesterol (LDL) in people with high visceral fat.

[3] A food composition for controlling blood glucose level and preventing fat accumulation, comprising a peptide extracted from the ovary rind of salmon as a main component.
This food composition has an effect of stably maintaining the blood glucose level by suppressing an increase in the blood glucose level.

[4] A food composition for controlling blood pressure and preventing fat accumulation, characterized by comprising as a main component a peptide extracted from the ovary skin of salmon.
The food composition inhibits the action of the ACE blood pressure increasing enzyme by ACE inhibitory activity, prevents blood pressure from rising, and acts so that the blood pressure becomes an optimum value.

[5] A food composition for improving the whitening effect and preventing fat accumulation, comprising a peptide extracted from the ovary husk of salmon as a main component.
According to this food composition, it is effective for moisturizing the skin, has an effect of improving dullness of the skin, is effective in improving the brightness and transparency of the skin, and is effective in improving small pigmentation and spots. Therefore, the whitening effect can be improved.

[6] A food composition for improving menopause and preventing fat accumulation, characterized by comprising a peptide extracted from the ovary skin of salmon as a main component.
The food composition can also improve symptoms such as rough skin, insomnia, coldness, and menstrual irregularities as climacteric disorders.

  According to the food composition for preventing fat accumulation according to the present invention, not only the improvement of metabolic syndrome by preventing fat accumulation, but also the suppression of liver function, blood sugar level control, blood pressure control, whitening effect improvement, and menopausal disorder improvement. Can also demonstrate excellent efficacy.

It is a graph which shows the result of the component analysis of a food composition (SOP). It is a chart which compares the content ratio of an amino acid among the component analysis of a food composition (SOP) with the placenta extract derived from an animal. It is a graph which shows the cumulative amount of calories among the results of animal experiment I. It is a graph which shows a body weight change among the results of the animal experiment I. It is a graph which shows fasting blood glucose among the results of the animal experiment I. It is a graph which shows neutral fat among the results of animal experiment I. It is a graph which shows the mRNA expression of UCP-1 in a white adipose tissue among the results of animal experiment I. It is a graph which shows the mRNA expression of FAS and ACC1 in a white adipose tissue among the results of animal experiment I. It is a graph which shows the mRNA expression of ACDH and ACO1 in a white adipose tissue among the results of the animal experiment I. It is a microscope picture of the rat primary visceral fat cells on the 0th day of administration of the test substance in animal experiment II. It is a microscope picture of the rat primary visceral fat cells on the second day of administration of the test substance in animal experiment II. It is a microscope picture of the rat primary visceral fat cells before the addition of norepinephrine on the fourth day of administration of the test substance in animal experiment II. It is a microscope picture of a rat primary visceral fat cell after addition of norepinephrine on the fourth day of administration of a test substance in animal experiment II. It is a microscope picture of the brown adipocyte before norepinephrine addition in the animal experiment II. It is a microscope picture of the brown fat cell after norepinephrine addition in the animal experiment II. It is explanatory drawing which shows the schedule of a single intake test. It is a table | surface which shows the evaluation and observation item of a single intake test. It is explanatory drawing which shows the schedule of a continuous ingestion test. It is a graph group which shows the data regarding lipid metabolism among the results of a continuous ingestion test. It is a graph group which shows the data regarding a liver function parameter | index among the results of a continuous ingestion test. It is a graph group which shows the data regarding a liver function parameter | index among the results of a continuous ingestion test. It is a graph group which shows the data regarding a blood glucose level and HbA1c among the results of a continuous ingestion test. It is a graph group which shows the data regarding systolic blood pressure among the results of a continuous ingestion test. It is a graph group which shows the data regarding a diastolic blood pressure among the results of a continuous ingestion test. It is a graph group which shows the data regarding the water | moisture content of skin among the results of the monitor test of various menopausal symptoms. It is a graph which shows the data regarding the roughness of the skin among the results of the monitor test of various menopausal symptoms. It is a graph which shows the data regarding the oil content of skin among the results of the monitor test of various menopausal symptoms. It is a graph which shows the data regarding the brightness of the skin among the results of the monitor test of various menopausal symptoms. It is a graph which shows the data regarding the dullness of skin among the results of the monitor test of various menopausal symptoms. It is a graph which shows the data regarding the skin texture among the results of the monitor test of various menopausal symptoms. It is a graph which shows the data regarding the smoothness of skin, makeup paste, and makeup mochi among the results of the monitor test of menopausal symptoms. It is a graph group which shows the data regarding the pigmentation (small) of skin among the results of the monitor test of various menopausal symptoms. It is a graph which shows the data regarding the pigmentation (large) of skin among the results of the monitor test of various climacteric symptoms. It is a graph which shows the data regarding the number of pores of skin among the results of the monitor test of various menopausal symptoms. It is a graph which shows the data regarding the number of wrinkles of skin among the results of the monitor test of various menopausal symptoms. It is a table | surface which shows the result of the self-scoring of the menopause index in the monitor test of the menopausal symptoms, and an evaluation method. It is a graph which shows the change of the menopause index in the monitor test of the menopausal symptoms.

Hereinafter, specific embodiments of the present invention will be described.
[Outline of food composition]
The food composition of the present invention is mainly composed of a peptide extracted from the ovary rind of salmon and is called Salmon Ovary Peptide by the present applicants. “Ovary” means ovary and is named SOP (registered trademark) in the sense of a functional amino acid peptide extracted from the ovary of salmon.

  SOP is a freeze-dried peptide obtained by hydrolyzing the string-like streak (ovary rind) remaining after processing from salmon (Salmonidae) into salmon roe by enzyme and then extracting it. It is. Its properties are light yellow or yellowish brown powder with a unique smell. The classification of SOP is health food raw material, and the name of the food raw material is salmon-derived placenta-like substance (scalpel ovary skin hydrolyzed extract). In addition, when using SOP as a cosmetic raw material, the name will be a sputum ovary skin hydrolysis extract.

  In general, in the case of animal-derived food compositions, the effects of bovine spongiform encephalopathy (BSE), foot-and-mouth disease, and other viruses and antibiotics cannot be denied. There is not much worry about. Although it is a shark that is relatively easy to procure ovarian rind of fish, the shark does not give birth many times unlike animals, so the amount that can be taken from a single female shark is only about 1 g. The raw material cocoon is limited to Japan (Hokkaido). This is because imported salmon from overseas or aquacultured salmon cannot be used because all of the built-in salmon is removed from the quarantine.

  In the Islamic region, placenta (placenta) derived from terrestrial animals may be avoided for religious reasons, but can be used as a food composition if derived from fish. In addition, compared to the case where the placenta of mammals is used as a raw material, few people feel uncomfortable with fish-derived SOP. In particular, it can be said that the ovarian husk of the moth has no resistance since it has a long-standing dietary habit of processed food.

[Preparation of food composition]
As a method for preparing the SOP, for example, a manufacturing method described in Patent Document 1 may be used. That is, after removing blood from the ovary husks of sputum, it is washed with cold water, and after washing, it is preferably treated with ozone water at room temperature or lower. By treatment with ozone water, sterilization and defatting of attached bacteria are performed, and further, denaturation of contractile protein (myosin) of myofibrillar protein, which is a constituent protein, is prevented.

  The ozone water treatment is performed at room temperature or lower for 5 to 30 minutes by supplying the ozone concentration of 0.2 to 10 ppm / L from the ozone generator while stirring the washed and dehydrated ovarian skin in a tank containing cold water. The ozone treatment liquid in which the ovarian husk is present in a dispersed state is heated to an enzyme reaction temperature of around 35 to 50 ° C. with stirring in order to eliminate the dissolved ozone.

  After ozone disappears, it is hydrolyzed with enzymes. For example, contractile protein (myosin) is degraded by a proteolytic enzyme produced by Bacillus. In this degradation solution, the enzyme in the degradation solution is heated directly to a temperature of 80 ° C. or higher, stirred for 15 minutes or more to deactivate the enzyme, and then further degraded with a protease produced by filamentous fungi. And digestion of bitterness and amino acid odor derived from other types of fish egg protein. The treatment with both enzymes is performed on the ovary skin using 0.02 to 0.2% by weight of the enzyme under stirring, at a treatment temperature of 55 ° C. and for a treatment time of 5 hours.

  After the enzyme treatment is deactivated, the treatment liquid after the enzyme treatment is subjected to centrifugal separation using an 800 mesh filter cloth, and further, colloidal impurities are removed by ultrafiltration. The filtrate containing the obtained peptide is concentrated to an appropriate concentration, and from the viewpoint of avoiding decomposition of the component as much as possible by freeze-drying method, etc. Become. As described above, the freeze-dried product has a peculiar smell with a pale yellow to yellow-brown powder. However, when packaging and packing as a product, it is odorless so that the appearance and taste cannot be identified. It is recommended to prepare a white powder.

[Ingredient analysis of food composition]
As a result of the component analysis, the obtained food composition (hereinafter referred to as “SOP”) has been found to contain the components shown in FIG. As for the amino acids constituting the peptides contained in SOP, as a result of component analysis, as shown in FIG. 2, in the comparison with the placenta extract derived from animals, There is no significant difference in the constituents of essential amino acids except that no phenylalanine content is observed.

In addition, other structural features of amino acids in SOP are that tyrosine, proline, glycine, and hydroxyproline are many and cysteine is small. SOP is expected to have special effects on fatty acid utilization and sugar utilization as a peptide, similar to porcine placenta extract, because fatty acid utilization and carbohydrate utilization are particularly active in the ovary during salmon ovarian maturation.
From the analysis of the raw materials for SOP and the component analysis of SOP, there were no residual pesticides, other toxic metals and non-ferrous metals, and no harmful substances were found.

[Animal Experiment I]
As a result of administering SOP to rats and conducting a safety test in small animals, SOP was not toxic and no problem was observed in safety. Based on these results, in order to determine the effectiveness of fat accumulation prevention, which is one of the functions of SOP, an experiment on metabolic syndrome targeting mice was conducted.

1. Experimental Method (1) Animals Used 15 6-week-old mice were used, and 5 mice (n = 5) were grouped into 3 groups, Normal, Control and SOP. Here, the Normal group is a group that does not load forced swimming (-) and feeds a normal diet (CE-2 (registered trademark)). The Control group is a group that loads forced swimming (+) and feeds a high fat diet (HFD32 (registered trademark)). The SOP group is a group in which forced swimming is loaded (+), a high fat diet (HFD32) is fed, and SOP is administered.

(2) Breeding method Breeding was carried out using individual stainless steel cages in an environment of room temperature (23 ± 2 ° C.), relative humidity 50-60%, and 12 hours light-dark cycle (7: 0 to 19:00).
The mice were fed freely with solid feed (CE-2) as a normal diet, solid feed (HFD32) as a high fat diet, and water for about 3 months (11 weeks).
The SOP was adjusted with physiological saline so as to have a set concentration (100 mg / kg), and then immediately orally administered to mice in the SOP group by gavage.
About forced swimming, during the implementation period, forced swimming for 10 minutes a day at a water temperature of 28 ° C. was loaded three times a week (in principle, Monday, Wednesday, and Friday).
In the dissection of the experiment end date, all groups of mice were fasted for 16 hours.

(3) Evaluation items 1) Food intake (calorie intake), body weight, peri-testicular white fat weight, periosteal brown fat cell weight 2) Blood biochemistry: fasting blood glucose, triglycerides, total cholesterol, HDL 3) Blood antioxidant activity: Antioxidant activity (TEAC), lipid peroxide (LPOTEAC) level 4) White adipose tissue mRNA: UCP-1, fattyacidsynthase (FAS), acetyl-CoA carboxylase1 (ACC1)
5) Liver mRNA: acy1-CoA dehydrogenase (ACDH), acy1-CoA oxidase1 (ACO1)

2. Experimental results (1) Calorie intake (food intake)
FIG. 3 shows the cumulative amount of calories consumed by each group of mice during the experimental period. As a result, the caloric intake in the Control group and SOP group ingesting a high fat diet was higher than in the Normal group ingesting a normal diet.
(2) Change in body weight FIG. 4 shows changes in body weight during the experimental period of mice in each group. As a result, the body weights of the Control group and the SOP group that ingested the high fat diet increased significantly compared to the Normal group fed with the normal diet.
In the SOP group, a significant body weight suppression effect was observed as compared to the Control group.

(3) Blood biochemistry test 1) Fasting blood glucose FIG. 5 shows the value of fasting blood glucose after the experiment of the mice in each group. As a result, compared with the Normal group fed with a normal diet, the Control group and SOP group that consumed a high fat diet showed a significant increase in blood glucose.
Moreover, the tendency which suppresses a blood glucose level was recognized in the SOP group compared with the Control group.
2) Neutral fat FIG. 6 shows the value of neutral fat after the end of the experiment for each group of mice. As a result, in the SOP group and the Control group, there was no effect of forced swimming or an increase in neutral fat due to a high fat diet.
In the SOP group, the neutral fat was lower than that in the Normal group and the Control group.
3) Total cholesterol, HDL, insulin, leptin A significant increase was observed in the Control group and SOP group ingested the high fat diet compared to the Normal group, but in these cases, the effect of SOP addition was observed. There wasn't.
4) Antioxidant activity in blood TEAC and LPOTEAC
Regarding these, administration of SOP measured a little antioxidant activity compared with the Normal group and the Control group.
Moreover, since there was no difference between the Normal group and the Control group, there was no increase in oxidative stress due to high-fat diet loading in this experiment.
Furthermore, administration of SOP did not affect LPO values.

(4) White adipose tissue (WAT) mRNA analysis UCP-1
UCP-1 is a kind of protein in mitochondria and has the function of burning fat in the inner membrane of the cell membrane to generate heat. It is known that the function of UCP-1 is reduced in obese animals.
FIG. 7 shows the value of UCP-1 mRNA expression in white adipose tissue after the experiment of each group of mice. As a result, ingestion of a high fat diet significantly reduced UCP-1 mRNA expression in white adipose tissue (Comparison between Normal and Control).
The SOP group significantly increased compared to the Control group, and recovered to the same expression level as the Normal group.

(5) White adipose tissue (WAT) mRNA analysis FAS, ACC1
FAS is a multi-active domain enzyme protein that synthesizes fatty acids from malonyl-CoA and acetyl-CoA. ACC1 is a kind of enzyme that synthesizes malonyl-CoA from acetyl-CoA, is involved in the regulation of fatty acid synthesis and fatty acid β-oxidation, and is mainly expressed in the liver and adipose tissue.
FIG. 8 shows mRNA expression of FAS and ACC1 in white adipose tissue after completion of the experiment for each group of mice. As a result, both FAS and ACC1 mRNA involved in fat synthesis showed the same tendency, and the mRNA level decreased due to high fat diet loading.
In the SOP group, it became clear that the mRNA level was comparable or higher than that in the Normal group.

(6) Liver mRNA analysis ACDH ACO1
ACDH and ACO1 are both types of lipid metabolism-related enzymes and are involved in lipid metabolism (β oxidation).
FIG. 9 shows the mRNA expression of ACDH and ACO1 in the liver after completion of the experiment for each group of mice. As a result, mRNA levels of these enzymes were increased in the SOP group.

As described above, as a result of examining the effect of SOP on metabolic syndrome using a high fat diet load model in mice, it is possible to reduce body weight gain and blood triglyceride content by ingesting a high fat diet. The usefulness against the syndrome was suggested.
The recovery of the UCP-1 mRNA level to the normal level in white adipose tissue was a result supporting the results of the cell experiment.
In the metabolic syndrome, the qualitative change in which fat cells are enlarged is regarded as a problem, as is the increase in visceral fat cells. The increase in mRNA expression of fat synthesis-related enzymes (FAS, ACC1) and lipolysis-related enzymes (AC01, ACDH) by the administration of SOP is considered to cause fat turnover.
Thereby, according to SOP, the expression of the protein (UCP-1) which burns the neutral fat of a white adipocyte is raised. That is, adrenaline acts, and mitochondria burn white fat cells (visceral fat cells) and convert them into brown fat cells. Thereby, the metabolic syndrome is improved.

[Animal Experiment II]
Using rat primary visceral fat cells (VAC), the effect of SOP on UCP-1 gene expression level was examined in vitro.
1. Test material (1) Test substance SOP was added to visceral adipocyte differentiation medium (primary cell, Lot. No. 071225) to a final concentration of 400, 100, 50 μg / mL.
(2) Negative control substance An additive-free visceral adipocyte differentiation medium (primary cell, Lot. No. 071225) was used.
(3) Cells used Visceral fat cell culture kit V-1 (primary, rat, primary cell: Lot. No.GI2A-F) and brown adipocyte culture kit F-1 (primary, rat, primary cell: Lot. No. HCEA-4) was used.
(4) Norepinephrine (hereinafter NE)
(-)-Norepinephrine (+)-bitartratesalthydrate (SIGMA: Lot No. 103K0979) was used.
(5) Preparation of Celllysate
TRI-Reagent (Molecular Research Center: Lot No.3681) was used.

2. Test method (1) Culture operation 1) Visceral fat cells (VAC)
Visceral fat precursor cells 3.0 × 10 6 cells were seeded in a 24-well plate (cell number was 1.2 × 10 5 cells / mL / well) and precultured with visceral adipose differentiation medium for 4 days. After the preculture (4 days after seeding), the negative control substance and the test substance were prepared with a visceral fat differentiation medium to a prescribed concentration, and the prepared medium was added to the cells.
The medium was exchanged on the 0th, 2nd and 4th days (seeding days 4, 6 and 8) after addition of the test substance, and a freshly prepared medium was added after the collection. On the last day, RNA is extracted as it is in the NE-untreated group, and in the NE-treated group, the test substance is adjusted to the specified concentration, and NE is extracted at 1 × 10-6M concentration with visceral adipose differentiation medium 6 hours before RNA extraction. Prepared and added to cells. Microscopic observation was performed on the test substance addition date and before and after the NE addition, and representative examples were photographed with a Hoffman module lens.

2) Brown adipocytes (BAT)
Brown adipocytes seeded in a 24-well plate were cultured in a growth medium for 3 days to confirm that they became confluent. The culture medium was replaced with a differentiation-inducing medium and cultured for 48 hours. Negative control substances and test substances were prepared with a maintenance medium at a prescribed concentration, and the prepared medium was added to the cells. The medium was replaced on the 0th, 2nd, 4th, and 5th days after addition of the test substance, and a freshly prepared medium was added after the collection. For NE treatment, the same treatment as VAC was performed with maintenance medium. Microscopic observation was performed before and after the addition of NE, and photographs of typical examples were taken using a Hoffman module lens.

(2) Preparation of Celllysate After completion of the culture, 400 μL of TRI-Reagent was added per well and pipetting was performed. Three wells were sealed in one Eppendorf tube and immediately stored frozen at −80 ° C.

(3) Extraction of RNA After thawing the sample, it was incubated at room temperature for 10 minutes or more. After adding 200 mL of chloroform and stirring with a vortexmixer for 30 seconds, phase separation was performed by centrifugation at 20,000 × g for 10 minutes at 4 ° C. The supernatant was collected in another 1.5 mL tube, and the same amount of cold isopropanol as the supernatant was added and stirred, followed by incubation for 10 minutes, and RNA was precipitated by centrifugation at 20,000 × g for 10 minutes at 4 ° C. The supernatant was removed, washed with 1 mL of 70% ethanol, centrifuged at 20,000 × g for 5 minutes at 4 ° C. to remove the supernatant, and air-dried. DEPC-treated purified water was added thereto to make a total RNA solution. The concentration of the obtained RNA solution was calculated by measuring the absorbance at 260 nm using an absorptiometer.

(4) Total RNA reverse transcription reaction
1stStrand cDNA Synthesis kit for RT-PCR (AMV) (Roche) was used. 2.5 mg of extracted and purified total RNA was diluted with RNaseFreeWater to make 23.2 mL. To this, 10 × ReactionBuffer 5 mL, 25 mM MgCl 210 mL, Deoxynucleotide Mix 5 mL, and Random Primer 5 mL were added, stirred well, spun down, and incubated at 65 ° C. for 5 minutes. 1 mL of RNase Inhibitor and 0.8 mL of AMVReverseTranscriptase were added and incubated at room temperature for 10 minutes, then at 42 ° C. for 60 minutes, and then at 95 ° C. for 5 minutes to synthesize cDNA.

(5) Real-time PCR
Real-time PCR was performed using the Applied Biosystems 7500 RealTime PCR System (Applied Biosystems, Foster City, Calif.) According to the standard TaqMan PCR kit protocol.
TaqManUniversalPCRMasterMix, rodentGAPDH and ratucp-1 primer / probe were all purchased from AppliedBiosystems. A 50 mL PCR reaction solution containing 5 mL RT product, 2 × TaqManUniversal PCR MasterMix, 0.25 mM MTaqManprobe, 0.9 mM forwardprimer and 0.9 mM reverseprimer was used. The reaction was carried out on a 96-well plate, and the reaction conditions were 10 minutes at 95 ° C., followed by 40 cycles of a program of 1 minute at 60 ° C. for 15 seconds at 95 ° C.

3. Test results (1) Photomicrograph of cell morphology (VAC)
1) Day 0 of administration of test substance (Day 4 of sowing)
On the 4th day after seeding the visceral fat cells, 1 mL of the culture solution prepared for each test substance was added, and microscopic observation and photography of representative examples were performed.
As shown in the micrograph of FIG. 10, when the whole of each well was observed, it was confirmed that fat droplets started to accumulate in the fat cells.
There was no difference between each group, confirming that the test system was conducted under the same conditions for each group.

2) Test substance administration day 2 (seeding day 6)
As shown in the micrograph of FIG. 11, in the negative control group, adipocytes that accumulated small lipid droplets were also observed, but many mature adipocytes were observed. In addition, the number of enlarged fat cells began to increase slightly.
In the SOP 50 μg / mL addition group, compared with the negative control group, there were many adipocytes that accumulated small lipid droplets, and almost no enlarged fat cells were observed.
Compared with the negative control group and the 50 μg / mL addition group, the number of adipocytes that accumulated small lipid droplets was similar in the SOP 100 μg / mL addition group, but mature and hypertrophic adipocytes There were few.
Compared with the negative control group, the 50 μg / mL addition group, and the 100 μg / mL addition group, the SOP 400 μg / mL addition group showed more fat cells that accumulated small lipid droplets, but the number of mature adipocytes was still smaller. It was.
No cell damage was observed in any group.

3) Test substance administration day 4 (seeding day 8) Before NE addition As shown in the micrograph of FIG. 12, in the negative control group, most adipocytes become mature cells and many cells are enlarged. It was.
In the SOP 50 μg / mL addition group, mature adipocytes increased. In addition, some fat cells were enlarged, but the number of fat cells enlarged was small compared to the negative control group.
In the SOP 100 μg / mL addition group, more fat cells accumulated smaller fat droplets than in the 50 μg / mL addition group, and there were fewer mature fat cells. In addition, the number of enlarged fat cells was small.
In the SOP 400 μg / mL addition group, there were many adipocytes in which small lipid droplets accumulated, compared with the negative control group, the 50 μg / mL addition group, and the 100 μg / mL addition group. There were a few mature fat cells and enlarged fat cells, but the number of fat cells was small.
No cell damage was observed in any group.

4) Test substance administration day 4 (seeding day 8) After NE addition As shown in the micrograph of FIG. 13, in the negative control group, cells with reduced lipid droplets were also observed, but there was not much change. Many cells and bloated cells were also seen.
In the SOP 50 μg / mL addition group, there were many cases in which lipid droplets were reduced, but enlarged lipid droplets were also observed in the same degree as the negative control.
In the SOP 100 μg / mL addition group, more adipocytes with reduced lipid droplets were seen and fewer cells remained unchanged than in the 50 μg / mL addition group. The enlarged fat droplets were slightly smaller than those in the 50 μg / mL addition group.
In the SOP 400 μg / mL addition group, more adipocytes with smaller lipid droplets were observed and more adipocytes with smaller lipid droplets were observed than in the 100 μg / mL addition group. Enlarged fat droplets were observed in the same degree as in the 100 μg / mL addition group.

(2) Microscopic photograph of cell morphology (BAT)
1) Before NE addition As shown in the micrograph in FIG. 14, in the negative control group, most of the fat cells became mature cells, and many cells were enlarged.
In the SOP 400 μg / mL addition group, more adipocytes in which many small lipid droplets were accumulated than in the negative control group were observed.
No cell damage was observed in any group.
2) After NE As shown in the micrograph of FIG. 15, in both the negative control group and the SOP 400 μg / mL addition group, most adipocytes react faster than VAC, and morphologically change significantly after 1 hour. It could be confirmed.
In the SOP 400 μg / mL addition group, a large difference was not confirmed from the morphological change compared to the negative control group.

(3) Results of gene expression analysis
In VAC, the expression of UCP-1 gene when NE was not added was below the detection limit, and even in the test substance-administered group, it was below the detection limit in all groups.
In the VAC NE treatment group, UCP-1 gene expression was observed in all groups.
In the VAC NE treatment group, the SOP 400 μg / mL addition group showed a higher UCP-1 gene expression value than the control.
In BAT, UCP-1 gene expression was observed with or without NE treatment.
In the BAT NE-untreated group, the UCP-1 gene expression levels of the control and SOP 400 μg / mL added groups were almost the same.
In the BAT NE treatment group, the SOP 400 μg / mL addition group showed a slightly higher UCP-1 gene expression value than the control.

(4) Discussion In this study, the effect of suppressing fat accumulation was examined. When morphological changes of fat cells were observed from the 2nd day to the 4th day after administration of the test substance, SOP showed that the number of enlarged fat cells Since it was less than the negative control group, it was speculated that the effect of suppressing the transition from matured adipocytes to enlarged fat cells could be expected rather than the effect of suppressing fat accumulation.
Although the high dose group of SOP was set to 400 μg / mL, no cytotoxicity was observed even on the 8th day of seeding. Therefore, even if a large amount of SOP is ingested, it is a substance that does not harm visceral fat cells. It was inferred that there was.
From the results of UCP-1 gene expression analysis, both visceral adipocytes and brown adipocytes tended to increase the expression level of UCP-1 gene at the time of NE addition in the SOP addition group. It was suggested that there may be an effect of promoting the heat production reaction by brown fat formation of cells or improvement of NE reactivity of brown fat cells.
From the above, SOP is considered to have an anti-obesity effect by improving the heat production reaction of adipocytes without adversely affecting the fat cells in the body even if overdose.

[Single intake test]
Based on the results of the animal experiments described above, a single-dose study was conducted for healthy subjects with the aim of determining the possibility of development of SOP as a functional food and safety in humans. .

1. Test method Changes in physical findings and laboratory test values were confirmed by a comparative study between two randomized open parallel groups of SOP 125 mg and 625 mg in healthy male subjects.
(1) Subjects Twelve men aged 20 to under 60 at the time of obtaining consent were grouped into two groups of 6 in a random assignment so that age, weight, and BMI were equal. The subjects were subject to the absence of a clear underlying disease in their past and current medical history. In addition, excluding those with previous history of heart disease, cerebrovascular disease surgery, treatment history, hepatitis, liver disease history, history of treatment, history of mental illness, history of treatment, etc. Exclusion criteria were established.
(2) Test meal White powder containing 125 mg or 625 mg as SOP (distinguishable by appearance, taste, smell, etc.).

(3) Test Contents FIG. 16 shows a test schedule, and FIG. 17 shows test evaluation / observation items.
As shown in FIG. 16, after explaining the test contents to the subject and obtaining consent (examination (1)), the subject is hospitalized from the day before the test. Blood was collected 12 hours before the first day of hospitalization (Study (2)), fasting after 21:00, and refraining from drinking after 00:00. Subjects ingested the test meal only once on the second day of hospitalization, and immediately after that, 0:00 (examination (3)), 2 hours later (examination (4)), 6 hours later (examination (5)), 12 hours Later (test (6)), blood was collected.

(4) Evaluation items 1) Abnormal laboratory test values: During the administration before the start of the study, the amount of change and the rate of change in the laboratory test values after the administration were obtained and evaluated. The clinical test values here relate to the test items in FIG.
2) Blood pressure and heart rate: During the administration before the start of the test, the blood pressure after the administration, the amount of change in heart rate and the rate of change were obtained and evaluated.

2. Test results 1) Safety Regarding physical findings prior to the start of intake of the test meal, adverse events and noteworthy changes in the investigation up to 24 hours after intake were as follows: low dose group (125 mg), high dose group (625 mg) None of these were recognized.
2) Effect of test meal In the high-dose group, a decrease in γ-GTP was observed after ingestion compared to the low-dose group. γ-GTP is said to be released into the blood due to increased permeability of hepatocyte membranes in an overloaded state of cells during the detoxification process of hepatocytes.
Clinically, it is considered an indicator of liver detoxification function. An increase in blood γ-GTP due to alcoholic liver injury, fatty liver, etc. has been reported.
From the results of this test, it can be determined that SOP has a function of suppressing a decrease in liver function.

[Continuous intake test]
A continuous ingestion test was conducted for the purpose of confirming long-term safety by quoting a drink containing SOP for subjects who meet any of the criteria for metabolic syndrome.

1. Test Method The effects of SOP on the various metabolic syndrome indicators were searched, and the liver function improvement effect was also examined as a secondary evaluation item.
(1) Subjects 28 men and women who were 20 years old or older and less than 60 years old when consent was obtained were grouped into two groups of 14 people, one in the SOP group and the other in the placebo group (B group). The subjects were conditioned on the absence of a clear underlying disease in the past and current medical history. In addition, excluding those with previous history of heart disease, cerebrovascular disease surgery, treatment history, hepatitis, liver disease history, history of treatment, history of mental illness, history of treatment, etc. Exclusion criteria were established.
(2) Test drink A drink (50 ml) containing 500 mg as SOP, or a placebo drink (containing no SOP).

(3) Test Contents FIG. 18 shows a test schedule.
As shown in FIG. 18, the test contents were first explained to the test applicant and consent was obtained, and then a preliminary test was performed on the person who entered the test. As a result of the preliminary test, 28 men and women who were confirmed to be eligible were grouped into 14 groups in 2 groups by random allocation so that age, weight and BMI were equal.
Every day during the 12-week study period, a drink containing 50 mg of SOP (50 ml) was taken in the SOP group, and a placebo drink (50 ml) was taken in the placebo group, one early in the morning or at breakfast. During the test period, blood collection, urine collection, and the like were performed at the start of the test (week 0), week 6, and week 12, respectively.

(4) Evaluation items 1) Abnormalities in clinical laboratory values: The amount of change and the rate of change in clinical laboratory values at the start of the test (week 0), weeks 6 and 12, were evaluated.
2) Blood pressure and heart rate: Blood pressure, changes in heart rate and rate of change at the start of the test (week 0), weeks 6 and 12, and evaluated.
3) In particular, the following items were examined as secondary evaluation items.
・ Changes in lipid index (neutral fat, LDL / HDL cholesterol)
・ Changes in liver function indices (γ-GTP, AST, ALT)
・ Changes in blood glucose index (blood glucose level, HbA1c)
・ Changes in blood pressure (systolic blood pressure, diastolic blood pressure)

2. Test results (1) Safety Regarding the subjects in the SOP group, no significant change in symptom of adverse events was observed after 12 weeks of continuous ingestion, confirming safety.
(2) Secondary evaluation items 1) Lipid metabolism As for clinical laboratory test values, there was no clear tendency between groups for the measured values of neutral fat and LDL / HDL cholesterol, as shown in FIG. Hierarchical analysis was performed.
As shown in FIG. 19 (a), no significant difference was observed in the neutral fat before intake of 150 ml / dL or more, but both the actual measurement value and the change amount showed a decreasing tendency in the SOP group. Therefore, in the case of a person with a high neutral fat value, the effect of improving the neutral fat value is estimated.
As shown in FIG. 19 (b), the increase in LDL cholesterol was more suppressed in the SOP group than in the placebo group in the amount of change at neutral fat before intake of less than 140 ml / dL. Therefore, in the case of a person with slightly high LDL cholesterol, it is presumed that there is an increase suppressing effect.
2) Liver function index (γ-GTP, AST, ALT)
FIG. 20 shows γ-GTP distribution and change (a), AST distribution and change (b), and ALT distribution and change (c) for each subject group and gender. Is shown. In each graph, “PM” is an abbreviation for a male in the placebo group, “PF” is an abbreviation for a female in the placebo group, “SOPM” is an male in the SOP group, and “SOPF” is an abbreviation for a female in the SOP group.
FIG. 21 shows the transition of γ-GTP distribution and change (a), AST distribution and change (b), ALT distribution and change (c) excluding outliers (for two people). ).
As shown in these results shown in FIGS. 20 and 21, no clear significant difference was observed, but all were in a decreasing trend. Furthermore, in AST and ALT, the SOP group tended to decrease. Therefore, SOP may be effective in improving liver function by suppressing liver function decline.

3) Blood glucose level, HbA1c
FIG. 22 shows changes in the blood glucose level for each observation time point and changes in the amount of change (a), and changes in the amount of HbA1c for each observation time point in the group and changes in the change amount (b).
As in the results shown in FIG. 22, the SOP group tended to suppress an increase in blood glucose level compared to the placebo group. In the SOP group, HbA1c tended to be suppressed to a low value.
HbA1c is a combination of hemoglobin contained in red blood cells with glucose, and is said to be an indicator of blood glucose control that reflects the average blood glucose level over the past 1 to 2 months from the test date. It is thought that there was an effect of maintaining the stability stably.

4) Blood pressure (systolic blood pressure, diastolic blood pressure)
FIG. 23 shows changes in the systolic blood pressure for each subject (a), men (b), and women (c) at each observation time point and changes in the amount of change.
FIG. 24 shows changes in the diastolic blood pressure for each subject (a), men (b), and women (c) at each observation time point and changes in the amount of change.
23 and 24, the systolic blood pressure tended to decrease in any group, and the diastolic blood pressure tended to decrease only in the placebo group.
SOP has been shown to have an ACE inhibitory effect in an in vitro test, and this action is thought to have reduced systolic blood pressure. The cause of the decrease in both systolic blood pressure and diastolic blood pressure in the placebo group is unknown.

[Monitoring test for improving menopausal symptoms]
Using SOP, 17 women who had menopausal symptoms but not enough to be treated were allowed to sample a SOP 500 mg drink every morning for 4 weeks and 8 (including 4 placebos) for 6 weeks (extended for 2 weeks) . Before tasting, after 1 week, after 4 weeks, after 5 weeks (after 1 week interruption), after 6 weeks, changes in skin condition were measured using Robo Skin Analyzer (registered trademark). In addition, blood was collected before tasting, after 4 weeks, after 5 weeks (after 1 week interruption) and after 6 weeks, and changes in the body were investigated using biochemical techniques. In addition, we investigated the menopause index and skin condition changes in the form of questionnaire responses.

  As a result, it was suggested that the skin was effective in terms of “smoothness”, “dullness”, “smoothness”, “makeup glue”, “makeup mochi”, “stain improvement”, and “pore tightening”. . Many have been aware of improvements in skin condition within a week. Interesting results were obtained, with almost all of them temporarily worsening at the time of the suspension, with the SOP restart group improving again, while the placebo group remained worse. This is a result supporting the skin improvement effect of SOP.

Blood test results showed no regularity in changes in vitamin groups, etc., but suggested the possibility of adjusting the balance of female hormones. In addition, there were many monitors that also improved the triglyceride level, suggesting the possibility of contributing to the improvement of lipid metabolism.
As for subjective changes, many monitors complained of improvements within one week for “recovering fatigue”, “improving sleep quality”, “improving sleep”, and “eliminating irritability”. Even after the change in menopause index, the index of all members improved every week, and the effect of symptom relief on menopausal women was also observed.

In this study, it was suggested that SOP500mg is effective in alleviating climacteric symptoms and improving skin condition in women. Since almost everyone was aware of the improvement effect on the skin and body within one week after the start, the immediate effect of this component could be confirmed.
Now that taking active ingredients from the inside has become established, it can be expected as a drink to prevent skin and fatigue and menopause.

1. Test method About 17 monitors, the measurement was performed 2-3 times before SOP tasting, 1 week after tasting, and 4 weeks after tasting <Study I>.
Furthermore, in the four monitors, after a tasting for 4 weeks, an interruption period of 1 week was provided (measured after 5 weeks), and the tasting for 1 week was resumed (measured after 6 weeks). In another 4 monitors, after a 4-week tasting, a 1-week interruption period was measured (measured as after 5 weeks), and another 1-week placebo tasting was performed (measured as after 6 weeks). <Study II> .
<Sample>
Drink with SOP 500mg <Monitor>
17 men and women aged between 35 and 55 who meet the following conditions.
・ With age, there are menopausal symptoms such as rough skin, insomnia (light sleep), fatigue, and stiff shoulders.
-The menopause index is 25 to 55 points (to the extent that the symptoms are worrisome but treatment is not yet required).
・ History of hormone treatments such as pills and HRT.
・ You currently have some illness and are not taking any other medicines. However, those who have a history of surgery for heart disease or cerebrovascular disease, history of treatment, history of hepatitis, liver disease, history of treatment, history of history of mental illness, history of treatment are excluded.
・ Do not take other health foods and supplements. Excluding those who have been taking health foods and vitamins for a long time.
・ Excluding those who participate in other clinical trials.

(1) About skin measurement Regarding <Test I>, the face was measured three times before tasting, 1 week after tasting and 4 weeks after tasting, using a Roboskin analyzer.
<Test II> was performed in the same manner as described above.
The measurement was performed after washing with soap for 15 minutes.
Robo Skin Analyzer RSA-100 (In-Forward) (hereinafter referred to as “Robo Skin”) fixes the face in a shooting box that emits scattered light, shoots the entire face with a high-resolution camera installed inside, and works as a digital image Analyze with a computer for image processing. The measured numerical value can be used for objective evaluation of the effect determination.
(Items that can be measured)
・ Facial moisture / oil content evaluation ・ Facial pigmentation site evaluation (number / area)
・ Facial pore evaluation (number / area)
・ Facial wrinkle evaluation (measurement of lower eyelid noodle wrinkles)
・ Face texture evaluation ・ Face brightness evaluation

(2) Blood test Regarding <Test I>, blood samples were collected twice before tasting and after 4 weeks of tasting, and component analysis was performed.
<Test II> was performed in the same manner as described above.
For blood tests, the amount of total protein, vitamins, zinc, iron, amino acids, basal metabolism, stress index, neutral fat, etc. were measured and their balance was analyzed based on numerical values.
(3) Changes in monitor self-reporting ・ Menopause index: Filled every day from the day of tasting to the last day ・ Skin questionnaire: In necessary items, responded with point (1-5) system Answer specifically

2. Test results and discussion The skin condition was evaluated as follows based on the results of ROBOSKIN and self-report.
(1) Moisture (actual value / rank)
The higher the amount of water, the more likely it is to be equivalent to the “smoothness” of the subjective symptom, which is judged to be fresh and moisturized skin.
FIG. 25 shows the evaluation results using Roboskin.
As shown in the bar graph in FIG. 25, there was almost no change in numerical values and ranks before tasting and after 1 week and 4 weeks after tasting. Considering that the climate was still warm before the tasting and that it was a time when the air suddenly got cold after 4 weeks and the air was very dry, there was no change between before the tasting and after 4 weeks Means that the skin was not dry even in winter, and the effect of tasting was considered.

FIG. 26 shows a 4-6 week self-assessment for “Katsu”.
“Sweetness” as a subjective symptom has improved in 16 out of 17 in the 4-week tasting of Study I. One was universal, and no one was getting worse. In addition, twelve people have noticed an improvement in “Katsutsuki” one week after tasting.
In addition, 6 of the 8 subjects who continued to participate in Study II and suspended tasting for 1 week had a worsening of “shaking” at the time of suspension (after 5 weeks). The two were unchanged. Three of the four people who resumed SOP had improved “spotting” after resumption (6 weeks later). One person was unchanged. On the other hand, 3 out of 4 placebo tastings showed no improvement in “Katsutsuki” and remained worse. One person was unchanged.
From the above results, it was considered that an improvement in “smoothness” was observed in one week of SOP tasting, and it was effective for moisturizing the skin.

(2) Oil content (rank)
The skin should not have too much or too little oil. If it is too much, it will become greasy and sticky, and if it is too little, it will become bulky. There is an amount appropriate for the age, and the more appropriate the amount for the skin, the higher the number of ranks (1-5 levels).
FIG. 27 shows an evaluation result by Roboskin.
In Study I, although a slight decrease in the numbers was observed after 1 week and 4 weeks after tasting, there was no significant difference. After 4 weeks of tasting, it was a time when the air suddenly became cold and the air was very dry, so it seems that there was a slight decrease in the oil content.

(3) Lightness (rank)
Lightness indicates the overall brightness of the skin. The higher the rank and number, the brighter the light and the darker the light. Here, the brightness of the skin is considered to be equivalent to the “dullness” of the subjective symptoms.
FIG. 28 shows the evaluation results using Roboskin.
In Test I, a slight increase was observed after 4 weeks of tasting compared to before tasting, and it was considered that the skin brightness was slightly improved, but no significant difference was observed.
FIG. 29 shows a self-assessment of 4 to 6 weeks regarding “dullness”.
The skin “dullness” as a subjective symptom was 8 patients who improved after 1 week in Test I, 6 who improved after 4 weeks, 3 who remained unchanged, and 0 who became worse. Furthermore, because of continuing participation in Study II, 5 of 8 subjects who suspended tasting for one week had a worsening of “dullness” at the time of suspension (after 5 weeks). The three were unchanged. Three out of four people who resumed SOP had improved “dullness” after resumption (after 6 weeks). One person was unchanged. On the other hand, 3 out of 4 placebo tastings did not improve “dullness” and remained aggravated or unchanged.
From the above results, it is considered that SOP has an effect of improving skin dullness and is effective in improving skin brightness and transparency.

(4) Texture (rank)
The texture indicates that the higher the rank, the finer the skin. The texture is considered to correspond to “smoothness”, “makeup paste”, and “makeup mochi” of subjective symptoms. FIG. 30 shows the evaluation results using Roboskin.
Compared to before the tasting, a slight increase in the value was observed one week after the tasting, and the effect was the same after four weeks. Although no significant difference was observed, it was considered that the skin texture tended to improve at an early stage, one week after tasting.

FIG. 31 shows self-evaluation for 4 to 6 weeks for “smoothness”, “makeup paste”, and “makeup mochi”.
In Study I, “smoothness” was improved in 9 subjects 1 week after tasting and 7 subjects after 4 weeks. One person was unchanged.
As for “Makeup Nori”, improvement was observed in 9 people after 1 week of tasting and 6 people after 4 weeks. The two were unchanged.
As for “Momochimochi”, improvement was observed in 11 persons 1 week after tasting and 2 persons after 4 weeks.
The four were unchanged.
In addition, 6 out of 8 people who suspended tasting for one week to continue participation in Study II, all of “smoothness”, “makeup paste”, and “makeup mochi” at the time of suspension (5 weeks later) It was getting worse. One person had a worsening of “makeup paste” and “makeup mochi”, “smoothness” remained unchanged, and the other was unchanged.
Three of the four people who resumed SOP improved one of “smoothness”, “makeup paste”, and “makeup mochi” after restart (six weeks later), “makeup paste”, “makeup” The improvement of only “mochi” was 1 person, the improvement of “smoothness” was 1 person, and 1 person was unchanged. The placebo group was considered to be clearly inferior in the improvement effect compared to the SOP restart group.

In addition, although there is an item of “Skin texture” in the subjective symptoms, the awareness of the texture is quite difficult, and the three items of “Smoothness”, “Makeup Nori”, “Makechimochi” are specific contents, and the state of the texture It was judged that it represents.
From the above results, it can be considered that the effect of improving the texture is recognized in one week of the SOP tasting, and it is effective for the smoothness of the skin, the makeup paste, and the makeup feeling.

(5) Pigmentation 1) Pigmentation (small) (actual value / rank)
FIG. 32 shows an actual measurement value (a) and a rank (b) of the evaluation result by Roboskin.
The number and the area of small pigmentation observed on the entire face were significantly decreased at 1 week and 4 weeks after tasting compared to before tasting.
Therefore, SOP is considered effective for small pigmentation.

2) Pigmentation (large) (actual measurement)
FIG. 33 shows the actual measurement values of the evaluation results using Roboskin.
Regarding so-called stains, in Test I, there was a slight decrease in the numbers at 1 week and 4 weeks after tasting, but there was no significant difference.
From the above 1) and 2), it can be considered that the fact that the number of large and small stains is reduced only by tasting without special external application for stains is effective for improving stains.

(6) Number of pores (actual measurement)
FIG. 34 shows the actual measurement values of the evaluation results using Roboskin.
The number of conspicuous pores was slightly lower after 1 week and 4 weeks after tasting than before tasting. From the fact that the number of conspicuous pores is reduced, it is considered that the effect of tightening the pores and making them inconspicuous can be expected.

(7) Number of wrinkles (actual value)
FIG. 35 shows the actual measurement values of the evaluation results using Roboskin.
The number of crepe lines under the eyes showed a slight decrease in the number of wrinkles at 1 week and 4 weeks after tasting, but there was no significant difference. The effect on wrinkles is considered difficult at this time.

(8) Changes in Menopause Index and Specific Changes due to Self-Reporting 1) Menopause Index Figure 36 shows the results of self-scoring of the menopause index and the evaluation method.
The menopause index was checked every day during the study period, but after 1 week in Study I, 16 out of 17 were 17 out of 17 after 17 weeks, 15 out of 17 after 3 weeks, 4 weeks later In 17 out of 17 people, the index decreased compared to before tasting, and some people had a maximum of -48.
Furthermore, because of continuing participation in Study II, the climacteric index at the time of suspension (after 5 weeks) was worsening in 8 out of 8 subjects who suspended the tasting for 1 week. In 4 out of 4 people who resumed SOP, the menopause index improved after resumption (6 weeks later). On the other hand, improvement was seen in 2 out of 4 placebo tastings. The two remained unchanged and remained in a deteriorated state.
FIG. 37 is a graph showing changes in the menopause index during the tasting period.
From this result, an improvement in the menopause index was observed in one week of SOP tasting, suggesting the possibility of being effective in alleviating climacteric symptoms.

2) Changes in specific subjective symptoms From one week onward, the monitor was able to feel improvement due to the effect of SOP on symptoms such as rough skin, insomnia, coldness, and menstrual irregularities as menopause. The visible effect created a sense of security to continue drinking, and it turned out that all four people are well-minded. It may be that the body became lighter and mentally stable by making it harder to feel tired.
On the contrary, some people returned to the state before tasting because the mental stabilizer disappeared by interruption and the effect of SOP could not be obtained. This drop is considered to demonstrate the effect on the skin and physical condition of tasting SOP. As evidence, skin and physical condition recovered in a few days by resuming tasting. In the placebo group, her physical condition returned to the same state as before the tasting. It is thought that it can support that you can get an effect by continuing to drink.

  As described above, the embodiments of the present invention have been described with reference to the drawings. However, the specific configuration is not limited to these embodiments, and the present invention can be modified or added without departing from the scope of the present invention. Included in the invention. For example, the present invention can be considered as a supplement in addition to a food composition.

  The food composition for preventing fat accumulation according to the present invention has excellent uses as described above, in particular, has characteristics of preventing fat accumulation and is not toxic. Therefore, in the health food industry and the pharmaceutical industry, As a raw material, it is highly likely to be widely used.

Claims (6)

  A food composition for preventing fat accumulation, comprising as a main component a peptide extracted from the ovary rind of salmon.   A food composition for suppressing a decrease in liver function and preventing fat accumulation, characterized by comprising a peptide extracted from the ovary skin of salmon as a main component.   A food composition for controlling blood glucose level and preventing fat accumulation, characterized by comprising a peptide extracted from the ovary skin of salmon as a main component.   A food composition for controlling blood pressure and preventing fat accumulation, characterized by comprising as a main component a peptide extracted from the ovary rind of salmon.   A food composition for improving the whitening effect and preventing fat accumulation, characterized by comprising a peptide extracted from the ovary skin of salmon as a main component.   A food composition for improving menopause and preventing fat accumulation, characterized by comprising a peptide extracted from the ovary skin of salmon as a main component.